Podcasts about mcrc

Pedro Manuel González, autor del libro «La Justicia en el Estado de partidos», en el capítulo nº 285 de «La lucha por el derecho» nos habla del proyecto de ley relacionado con la entrega de la instrucción penal a los fiscales. Os recordamos que el próximo 7 de diciembre volverá a representarse la obra de teatro Patología de la Transición, en el teatro Victoria de Madrid a las 19:00h. Podéis comprar las entradas en el siguiente enlace: https://www.giglon.com/todos?idEvent=patologia-de-la-transición. Por otro lado el próximo 8 de noviembre tendrá lugar la presentación del libro Tres Prólogos de Antonio García-Trevijano, en la Biblioteca Pública Iván de Vargas, situada en la calle San Justo nº5 de Madrid. Dicho acto será a las 11:00h. En el siguiente enlace pueden acceder a los artículos de Pedro Manuel González: https://www.diariorc.com/autor/pedromgonzalez --------- ¡APÓYANOS! - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

Pedro Manuel González, autor del libro «La Justicia en el Estado de partidos», en el capítulo nº 285 de «La lucha por el derecho» nos habla del proyecto de ley relacionado con la entrega de la instrucción penal a los fiscales. Os recordamos que el próximo 7 de diciembre volverá a representarse la obra de teatro Patología de la Transición, en el teatro Victoria de Madrid a las 19:00h. Podéis comprar las entradas en el siguiente enlace: https://www.giglon.com/todos?idEvent=patologia-de-la-transición. Por otro lado el próximo 8 de noviembre tendrá lugar la presentación del libro Tres Prólogos de Antonio García-Trevijano, en la Biblioteca Pública Iván de Vargas, situada en la calle San Justo nº5 de Madrid. Dicho acto será a las 11:00h. En el siguiente enlace pueden acceder a los artículos de Pedro Manuel González: https://www.diariorc.com/autor/pedromgonzalez --------- ¡APÓYANOS! - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

La forma apresurada con la que España entró en la Comunidad Económica Europea (CEE) entonces y hoy llamada Unión Europea condicionó la debilidad del Estado español dentro de la actual UE. Fuentes del audio: Radio libertad constituyente: https://www.ivoox.com/rlc-2018-01-26-piensa-veras-audios-mp3_rf_23386869_1.html Música: Allegro. BWV 1062. J.S.Bach. --------- - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info Música: Presto. BWV 1056. J.S.Bach. --------- - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info Música: Allegro. BWV 1062. J.S.Bach. --------- - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

Pedro Manuel González, autor del libro «La Justicia en el Estado de partidos», en el capítulo nº 284 de «La lucha por el derecho» nos habla del Estado como promotor de manifestaciones. Os recordamos que el próximo 7 de diciembre volverá a representarse la obra de teatro Patología de la Transición, en el teatro Victoria de Madrid a las 19:00h. Podéis comprar las entradas en el siguiente enlace: https://www.giglon.com/todos?idEvent=patologia-de-la-transición Por otro lado el próximo 8 de noviembre tendrá lugar la presentación del libro Tres Prólogos de Antonio García-Trevijano, en la Biblioteca Pública Iván de Vargas, situada en la calle San Justo nº5 de Madrid. Dicho acto será a las 11:00h. En el siguiente enlace pueden acceder a los artículos de Pedro Manuel González: https://www.diariorc.com/autor/pedromgonzalez --------- ¡APÓYANOS! - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

Los partidos pertenecen a la sociedad civil, hoy día los partidos y los sindicatos son estatales, sirven al régimen partidocrático. No hay representación política. Un partido estatal es una aberración. Mención a Gerardo Iglesias, ex-secretario general del PCE. Fuentes del audio: Radio libertad constituyente: https://www.ivoox.com/rlc-2018-01-26-piensa-veras-audios-mp3_rf_23386869_1.html Música: Allegro. BWV 1062. J.S.Bach. --------- - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info Música: Presto. BWV 1056. J.S.Bach. --------- - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info Música: Allegro. BWV 1062. J.S.Bach. --------- - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

Pedro Manuel González, autor del libro «La Justicia en el Estado de partidos», en el capítulo nº 283 de «La lucha por el derecho» analiza las consideraciones del auto del magistrado Leopoldo Puente que afectan a José Luis Ábalos. Os recordamos que ya podéis comprar la entradas para ver la obra de teatro Patología de la Transición: https://www.giglon.com/todos?idEvent=patologia-de-la-transicion En el siguiente enlace pueden acceder a los artículos de Pedro Manuel González: https://www.diariorc.com/autor/pedromgonzalez --------- ¡APÓYANOS! - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

El actual Estado de partidos es producto del consenso con el franquismo. No haber roto mediante la apertura de un período de libertad constituyente a la muerte de Franco provoca que la guerra civil esté en boca constantemente de la falsa izquierda. Como ejemplo de la falsa izquierda, Felipe González. Referencia al pensamiento de Antonio Gramnsci sobre el enriquecimiento de los jefes de los partidos de izquierda. Fuentes del audio: Radio libertad constituyente: http://www.ivoox.com/rlc-2016-09-28-hoy-pagamos-precio-no-audios-mp3_rf_13092645_1.html Música: Presto. BWV 1056. J.S.Bach. --------- - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

Pedro Manuel González, autor del libro «La Justicia en el Estado de partidos», en el capítulo nº 282 de «La lucha por el derecho» nos habla del principio moral que sostenía a la monarquía y el que debe sostener a una república. Os recordamos que ya podéis comprar la entradas para ver la obra de teatro Patología de la Transición: https://www.giglon.com/todos?idEvent=patologia-de-la-transicion En el siguiente enlace pueden acceder a los artículos de Pedro Manuel González: https://www.diariorc.com/autor/pedromgonzalez --------- ¡APÓYANOS! - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

Anécdotas de encuentros con Felipe González y el Rey Juan Carlos I. Durante la Transición española los partidos de la oposición traicionaron los ideales de la libertad política colectiva que previamente firmaron en la junta democrática de España. Fuentes del audio: Radio libertad constituyente: https://www.ivoox.com/rlc-2013-31-01-crisis-estado-crisis-la-audios-mp3_rf_1752434_1.html Música: Presto. BWV 1056. J.S.Bach. --------- - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

Pedro Manuel González, autor del libro «La Justicia en el Estado de partidos», en el capítulo nº 281 de «La lucha por el derecho» nos habla del jurado popular en relación al enjuiciamiento de Begoña Gómez. En el siguiente enlace pueden acceder a los artículos de Pedro Manuel González: https://www.diariorc.com/autor/pedromgonzalez --------- ¡APÓYANOS! - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

Don Antonio analiza las palabras de Mariano Rajoy el 30 de noviembre del 2014 tras el intento de sedición del llamado 9N. Fuentes del audio: Radio libertad constituyente: http://www.ivoox.com/rlc-2014-11-30-discurso-rajoy-cataluna-y-audios-mp3_rf_3798641_1.html Música: Allegro. BWV 1055. J.S.Bach. --------- - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

Pedro Manuel González, autor del libro «La Justicia en el Estado de partidos», en el capítulo nº 280 de «La lucha por el derecho» nos habla del discurso del rey en la ONU. En el siguiente enlace pueden acceder a los artículos de Pedro Manuel González: https://www.diariorc.com/autor/pedromgonzalez --------- ¡APÓYANOS! - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

Las primarias que se hacen en las partidocracias son pantomimas copiadas de la tradición democrática de Estados Unidos de América. Fuentes del audio: Radio libertad constituyente: https://www.ivoox.com/rlc-2016-02-02-albert-rivera-no-descarta-irse-a-audios-mp3_rf_10286907_1.html Música: Allegro. BWV 1055. J.S.Bach. --------- - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

Pedro Manuel González, autor del libro «La Justicia en el Estado de partidos», en el capítulo nº 279 de «La lucha por el derecho» nos habla del concepto de libertad constituyente. En el siguiente enlace pueden acceder a los artículos de Pedro Manuel González: https://www.diariorc.com/autor/pedromgonzalez --------- ¡APÓYANOS! - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

En el Estado de partidos no hay representación, solamente hay integración de las masas en el Estado. La no separación de poderes hace que el poder no pueda ser controlado. Fuentes del audio: Radio libertad constituyente: https://go.ivoox.com/rf/25624339 Música: Allegro. BWV 1055. J.S.Bach. --------- - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

Pedro Manuel González, autor del libro «La Justicia en el Estado de partidos», en el capítulo nº 278 de «La lucha por el derecho» nos habla de las consecuencias de la falta de representación política ante tragedias naturales. En el siguiente enlace pueden acceder a los artículos de Pedro Manuel González: https://www.diariorc.com/autor/pedromgonzalez --------- ¡APÓYANOS! - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

La unidad de la nación española garantiza la continuidad de España al margen de un Estado de partidos que constantemente intenta integrar masas en este. Fuentes del audio: Radio libertad constituyente: https://go.ivoox.com/rf/25624470 https://go.ivoox.com/rf/21758987 Música: Andante. Allegro. BWV 1052. J.S.Bach. --------- - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

Pedro Manuel González, autor del libro «La Justicia en el Estado de partidos», en el capítulo nº 277 de «La lucha por el derecho» analiza la apertura del año judicial. En el siguiente enlace pueden acceder a los artículos de Pedro Manuel González: https://www.diariorc.com/autor/pedromgonzalez --------- ¡APÓYANOS! - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

La monarquía de partidos no es una degeneración de la democracia. La corrupción y la sed de poder de los partidos estatales ha degenerado el régimen de partidos instaurado en 1978. Fuentes del audio: Radio libertad constituyente: https://go.ivoox.com/rf/25624339 Música: Allegro. BWV 1052. J.S.Bach. --------- - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WEP865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 28, 2026.Playing the Right Sequence in mCRC: Practical Strategies for Integrating Multi-Kinase Inhibitors in Later Lines of Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Colorectal Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WEP865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 28, 2026.Playing the Right Sequence in mCRC: Practical Strategies for Integrating Multi-Kinase Inhibitors in Later Lines of Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Colorectal Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WEP865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 28, 2026.Playing the Right Sequence in mCRC: Practical Strategies for Integrating Multi-Kinase Inhibitors in Later Lines of Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Colorectal Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WEP865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 28, 2026.Playing the Right Sequence in mCRC: Practical Strategies for Integrating Multi-Kinase Inhibitors in Later Lines of Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Colorectal Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Disclosure information is available at the beginning of the video presentation.

Pedro Manuel González, autor del libro «La Justicia en el Estado de partidos», en el capítulo nº 276 de «La lucha por el derecho» nos explica el concepto de conciencia republicana de España. En el siguiente enlace pueden acceder a los artículos de Pedro Manuel González: https://www.diariorc.com/autor/pedromgonzalez --------- ¡APÓYANOS! - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

In our conversation, Dr García-Carbonero discussed a subgroup analysis from the phase 3 FRESCO-2 trial (NCT04322539), which evaluated fruquintinib (Fruzaqla) in previously treated metastatic CRC (mCRC). She reviewed efficacy outcomes by metastatic site, including liver-only, lung-only, bone, and peritoneal disease. Fruquintinib demonstrated improvements in overall survival and progression-free survival across all subgroups, underscoring its feasibility in later-line settings for patients with mCRC. She also addressed prognostic differences between metastatic sites, noting that all patient groups derived benefit from treatment. Dr García-Carbonero also shared findings from PROMETCO, the first international, prospective, real-world study in mCRC, which is examining real-world outcomes for this patient population. 

In our exclusive interview, Dr Élez discussed recent data comparing nivolumab (Opdivo) monotherapy with nivolumab plus ipilimumab (Yervoy) across multiple lines of therapy in patients with MSI-H mCRC. She detailed efficacy and quality‑of‑life outcomes, noting that the combination appeared to offer enhanced clinical benefit without a negative effect on tolerability. Dr Élez also highlighted the importance of tailoring immunotherapy strategies based on patient characteristics and treatment goals and reflected on the nuances of sequencing single‑agent vs combination checkpoint blockade.

In today's episode, we had the pleasure of speaking with Connie Lai, MD, a medical oncology resident at Queen Elizabeth Hospital in Hong Kong, about a retrospective, dual-center study examining post-induction treatment strategies in metastatic colorectal cancer (mCRC).

Pedro Manuel González, autor del libro «La Justicia en el Estado de partidos», en el capítulo nº 275 de «La lucha por el derecho» nos explica por qué el falso currículum de Noelia Núñez no es un caso aislado. En el siguiente enlace pueden acceder a los artículos de Pedro Manuel González: https://www.diariorc.com/autor/pedromgonzalez --------- ¡APÓYANOS! - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

Sin cambiar el sistema proporcional de listas de partido ni la financiación a los partidos es imposible abrir un período de libertad constituyente y derrocar la oligarquía de partidos estatales. Fuentes del audio: Radio libertad constituyente: https://www.ivoox.com/rlc-2013-31-01-crisis-estado-crisis-la-audios-mp3_rf_1752434_1.html Música: Andante. Allegro. BWV 1052. J.S.Bach. --------- - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

Hoy publicamos un programa especial presentado y conducido por Marcelino Merino, donde Fulgencio Del Hierro analiza las diferentes capacidades de los países del Golfo Pérsico y la guerra de los 12 días entre Irán e Israel. También se analiza el papel de la OTAN y la aportación -excesiva- de España. --------- ¡APÓYANOS! - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/maximizing-outcomes-strategic-approaches-in-metastatic-crc-treatment/36513/ This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/advancing-molecular-therapies-to-first-line-in-braf-mutated-mcrc-insights-from-emerging-data/36506/ This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/case-consult-current-standards-and-emerging-directions-in-braf-mutant-mcrc-care/36508/ This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/maximizing-outcomes-strategic-approaches-in-metastatic-crc-treatment/36513/ This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/case-consult-current-standards-and-emerging-directions-in-braf-mutant-mcrc-care/36508/ This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/advancing-molecular-therapies-to-first-line-in-braf-mutated-mcrc-insights-from-emerging-data/36506/ This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

Pedro Manuel González, autor del libro «La Justicia en el Estado de partidos», en el capítulo nº 274 de «La lucha por el derecho» nos habla de cómo el consenso afecta negativamente a la Justicia. En el siguiente enlace pueden acceder a los artículos de Pedro Manuel González: https://www.diariorc.com/autor/pedromgonzalez --------- ¡APÓYANOS! - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

El factor de gobierno con el régimen del 78 es la corrupción. España sufre las consecuencias de no haber roto con el franquismo. Fuentes: Radio libertad constituyente: http://www.ivoox.com/rlc-2016-09-28-hoy-pagamos-precio-no-audios-mp3_rf_13092645_1.html Música: Andante. Allegro. BWV 1034. J.S.Bach. --------- - Vía iVoox: haz clic en APOYAR (botón de color azul). - Vía Paypal: https://www.paypal.com/donate?hosted_button_id=Y4WYL3BBYVVY4 - Vía Patreon: https://www.patreon.com/MCRC_es ------------ mcrc.es diariorc.com yonovoto.info

Please visit answersincme.com/KTK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal cancers discusses strategies for treatment of patients with colorectal cancer using tyrosine kinase inhibitors. Upon completion of this activity, participants should be better able to: Identify patients with metastatic colorectal cancer (mCRC) who are suitable for tyrosine kinase inhibitor (TKI) treatment; Outline practical, patient-centered strategies to maximize quality of life in patients receiving later-line TKI treatment for mCRC; and Review approaches to manage adverse events associated with later-line TKI treatment for mCRC.

Featuring perspectives from Dr Andrea Cercek, Dr Arvind Dasari, Dr J Randolph Hecht, Dr Pashtoon Kasi and Prof Eric Van Cutsem, moderated by Dr Hecht, including the following topics: Introduction (0:00) Role of Circulating Tumor DNA (ctDNA) Evaluation in Nonmetastatic Colorectal Cancer (CRC) — Dr Dasari (2:20) Role of Immune Checkpoint Inhibitors in the Management of Nonmetastatic Microsatellite Instability-High (MSI-H) CRC — Dr Cercek (28:32) Management of Oligometastatic Disease and Hepatic-Only Metastases in CRC; Role of ctDNA Evaluation in Metastatic Disease — Dr Kasi (54:07) Role of Immune Checkpoint Inhibitors in the Management of MSI-H Metastatic CRC (mCRC) — Dr Hecht (1:14:34) Identification and Care of Patients with mCRC and Actionable Genomic Alterations — Prof Van Cutsem (1:38:17) CME information and select publications

In this episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was rejoined by Midhun Malla, MD, of the University of Alabama at Birmingham, to discuss therapeutic options for patients with metastatic colorectal cancer (mCRC), particularly in the third-line setting and beyond. In the final part of this 3-part episode miniseries, Drs Park and Malla explored the challenges faced by community oncologists, especially in rural or underserved areas, in accessing clinical trials, which remain a preferred disease management approach due to their role in advancing novel therapies. However, in the absence of trial availability or when patients are ineligible, they emphasized the importance of evidence-based, FDA-approved agents for later lines of therapy. Three primary agents were discussed for patients who have progressed on first-line FOLFOX (folinic acid, fluorouracil, and oxaliplatin) and second-line FOLFIRI (folinic acid, fluorouracil, and irinotecan) regimens: trifluridine/tipiracil (TAS-102; Lonsurf) plus bevacizumab (Avastin); fruquintinib (Fruzaqla); and regorafenib (Stivarga). These agents offer viable treatment pathways in biomarker-unselected patient populations. However, direct comparisons between these agents are lacking, as most were tested against placebo controls. The choice among them is often individualized based on patient performance status, prior exposure to biologics, and toxicity profiles. TAS-102 plus bevacizumab has generated promising results, though real-world data may show diminished efficacy due to frequent prior exposure to 5-fluorouracil and bevacizumab in US patients. Fruquintinib offers a VEGF-targeted approach with a more favorable hematologic toxicity profile, whereas regorafenib is associated with notable adverse effects, including hypertension, gastrointestinal toxicity, and mucositis. Park and Malla emphasized the importance of treatment sequencing, toxicity management, and individualized patient-centered care, including consideration of dose modifications to preserve quality of life in later-line settings. In addition to later-line options, the conversation also touched on emerging frontline therapies. Notable investigational agents include zanidatimab-hrii (Ziihera) and KRAS G12C–directed therapies. Additionally, a novel integrin-targeted cytotoxin is currently under evaluation at the University of Alabama at Birmingham in patients with treatment-naive mCRC. This agent induces apoptosis via caspase-8 activation and has demonstrated encouraging preclinical activity. Overall, the discussion highlighted a nuanced, biomarker-informed, and patient-tailored approach to mCRC management, emphasizing both the value of clinical trials and the importance of optimizing currently available therapies.

In this episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was rejoined by Midhun Malla, MD, a gastrointestinal oncologist at Allegheny Health Network in Pittsburgh, Pennsylvania, to discuss treatment personalization in metastatic colorectal cancer (mCRC), with a focus on BRAF V600E–mutant tumors, HER2-altered disease, and the clinical implications of tumor sidedness.

A recent #study from Assiut University Hospital in Egypt, published in #Oncotarget, presents a promising strategy for patients with metastatic #colorectalcancer (mCRC). The #research introduces a gentler yet effective maintenance therapy that may extend survival, enhance quality of life, and offer a more accessible treatment option for mCRC patients worldwide. The Challenge of Treating Metastatic Colorectal Cancer Colorectal cancer is one of the most common causes of cancer-related deaths worldwide. When it spreads to other parts of the body—a stage known as mCRC—it becomes much more difficult to treat. At this stage, clinicians often use strong drug combinations like FOLFOX or CAPOX, which mix chemotherapy drugs to stop cancer growth. FOLFOX combines three drugs given intravenously, while CAPOX includes two of the same drugs, with one taken as a pill. While effective, these treatments can cause serious side effects. For example, one of the main drugs, oxaliplatin, can lead to nerve damage, making it painful or difficult to use the hands and feet. Fatigue, diarrhea, and other issues are also common. Over time, these side effects may force clinicians to stop or adjust the treatment, even if it is working. That is where maintenance therapy comes in. After the cancer is controlled, clinicians often switch to a gentler treatment plan to keep it from returning. The challenge is finding a therapy that continues to work without causing too many side effects, especially in places where access to expensive or intensive treatments is limited. Full blog - https://www.oncotarget.org/2025/05/07/panitumumab-and-low-dose-capecitabine-a-promising-maintenance-therapy-for-metastatic-colorectal-cancer/ Paper DOI - https://doi.org/10.18632/oncotarget.28687 Correspondence to - Doaa A. Gamal - doaaalygamaal@gmail.com Video short - https://www.youtube.com/watch?v=wuPSS0EdK-8 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28687 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, Panitumumab, maintenance, colorectal cancer, Capecitabine About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/CaseConsultAdverseEffectMonitoringManagementandMitigationDuringTargetedTherapyforBRAFMutantmCRc/33134/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/DefiningtheStandardofCareandOptimalSequencinginBRAFMutantmCRcSecondLineandBeyond/32944/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

Dr Fakih discusses the significance of this approval, key findings from the pivotal CodeBreaK 300 trial (NCT05198934), and how this combination fits into the current KRAS G12C–mutated mCRC treatment paradigm.

Featuring perspectives from Dr Arvind Dasari, Dr Christopher Lieu, Dr Van K Morris, Dr Jenny Seligmann and Prof Eric Van Cutsem, moderated by Dr Lieu, including the following topics: Introduction (0:00) Optimizing Biomarker Assessment for Patients with Colorectal Cancer (CRC) — Dr Dasari (2:18) Identification and Management of Metastatic CRC (mCRC) with a BRAF V600E Mutation — Dr Morris (26:37) Incorporation of Immune Checkpoint Inhibitors into the Management of Microsatellite Instability-High/Mismatch Repair-Deficient CRC — Dr Seligmann (49:46) Integration of Therapies Targeting HER2 into the Management of mCRC — Prof Van Cutsem (1:14:19) Biomarker-Based Decision-Making for Patients with mCRC and KRAS G12C Mutations — Dr Lieu (1:36:36) CME information and select publications

BUFFALO, NY - February 18, 2025 – A new #researchpaper was #published in Oncotarget, Volume 16, on February 12, 2025, titled “Could Panitumumab with very low dose Capecitabine be an option as a maintenance regimen." In this study, researchers Doaa A. Gamal, Aiat Morsy, and Mervat Omar from Assiut University Hospital, evaluated a new maintenance treatment for metastatic colorectal cancer (mCRC). Their findings suggest that a combination of two drugs—Panitumumab, a targeted therapy that blocks a protein called epidermal growth factor receptor to slow cancer growth, and low-dose Capecitabine, a chemotherapy drug that converts into 5-fluorouracil (5-FU) inside the body to stop cancer cells from growing and dividing—could help extend survival in patients with mCRC. This regimen appears to be both effective and well-tolerated, especially for patients with wild-type KRAS mCRC who had previously responded to treatment. Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. Standard treatment often involves a combination of chemotherapy and targeted therapies, but many patients face challenges related to treatment toxicity and resistance, which can lead to treatment interruptions. This study tested whether a lower-intensity maintenance treatment could help keep the cancer under control after initial treatment. The study involved 25 mCRC patients with wild-type KRAS and BRAF, who first received six rounds of standard 5-FU-based chemotherapy with Panitumumab. Patients who responded well then switched to a maintenance treatment of Panitumumab every two weeks and a low, continuous dose of Capecitabine. The results showed that patients had a median progression-free survival of 18 months and a median overall survival of 45 months, indicating a strong potential benefit. Patients with metastases detected at the same time as the primary tumor showed a longer progression-free survival than those with metastases appearing later. The treatment was also well tolerated, with only 8% of patients experiencing severe side effects such as skin rash or diarrhea, which were managed with standard treatments. "In our research, the toxicity profile was very acceptable, and no patients needed to stop treatment or had a dose modification due to toxicity." Finding a way to keep cancer under control while reducing side effects is a major goal in cancer treatment. While other maintenance therapies like Bevacizumab and Cetuximab have been studied, this research suggests that Panitumumab with low-dose Capecitabine could be a promising new option. Panitumumab is already an FDA-approved drug, but its role in maintenance therapy had not been extensively explored. The results of this study suggest that this combination may help delay disease progression while keeping side effects manageable, ultimately improving patients' quality of life. Although larger studies are needed, these findings open the door for further clinical trials to confirm the benefits of this regimen. If validated, this approach could change the standard of care for mCRC patients, particularly those who cannot tolerate more intensive chemotherapy. DOI - https://doi.org/10.18632/oncotarget.28687 Correspondence to - Doaa A. Gamal - doaaalygamaal@gmail.com Video short - https://www.youtube.com/watch?v=wuPSS0EdK-8 To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Please visit answersincme.com/BPB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in colorectal cancer discusses the latest guidelines and evidence for later-line treatment of metastatic colorectal cancer (mCRC), as well as strategies for treatment selection and survivorship care. Upon completion of this activity, participants should be better able to: Review guideline recommendations for the later-line treatment of mCRC; Discuss the clinical impact of approved later-line treatments in patients with mCRC; and Outline personalized strategies to optimize outcomes for patients with mCRC who require later-line treatment.

Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC